We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MANAGING PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA.
- Authors
Rodgers, George M.
- Abstract
Anemia is a relatively common condition in patients with cancer, with an incidence of 60% among patients with solid tumors/lymphoma and 70% to 90% among those receiving myelosuppressive chemotherapy and/or radiation therapy. This article offers a review of chemotherapy-induced anemia (CIA), as related to prevalence, etiology, patient outcomes, and the latest treatment strategy. The risks and benefits of current treatments (eg, packed red blood cell transfusions, erythropoiesisstimulating agents (ESAs), and iron supplementation), as well therapeutic recommendations from several guidelines on the management of CIA, are discussed in detail. Current guidelines emphasize an ongoing risk assessment of the patient with CIA, which takes into account symptoms, risk factors, and pertinent laboratory values. Guideline recommendations regarding ESA therapy are quite detailed and highlight the need to dose ESAs conservatively (maintaining hemoglobin levels <12 g/dL), use them in appropriate settings (ie, anemia related to myelosuppressive chemotherapy; avoid in patients with cancer who are not receiving chemotherapy), and discontinue them after completion of chemotherapy.
- Subjects
DRUG therapy; ANEMIA; LYMPHOMAS; RADIOTHERAPY; ERYTHROPOIESIS; THERAPEUTICS
- Publication
Johns Hopkins Advanced Studies in Medicine, 2008, Vol 8, Issue 10, p346
- ISSN
1530-3004
- Publication type
Article